Better AI Stock: BigBear.ai vs. Innodata
BigBear.ai's business is stabilizing as it gains more government contracts.
Innodata's business is booming as it processes more AI data.
One of these AI stocks looks like a more compelling investment.
10 stocks we like better than BigBear.ai ›
BigBear.ai (NYSE: BBAI) and Innodata (NASDAQ: INOD) represent two different ways to invest in the booming artificial intelligence (AI) market. BigBear.ai develops AI modules for edge networks, while Innodata helps large companies prepare their data for AI applications.
Over the past 12 months, BigBear.ai's stock surged more than 390% as it impressed investors with the stabilization of its business and the rollout of its biometric security services. Innodata's stock rose about 140% as the market's demand for its AI-oriented services soared. Should you still buy either of these high-flying AI stocks today?
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More »
The differences between BigBear.ai and Innodata
BigBear.ai's three main AI modules -- Observe, Orient, and Dominate -- ingest data, identify trends, and predict future outcomes, respectively. It installs its modules on edge networks, which receive and process that data before it reaches its clients' origin servers. It also shares that data with bigger AI-driven companies, such as Palantir.
Before BigBear.ai went public by merging with a special purpose acquisition company (SPAC) in late 2021, it claimed it could triple its annual revenue from $182 million in 2021 to $550 million in 2024. However, its revenue grew from $146 million in 2021 to only $158 million in 2024, as it grappled with tough competition, macro headwinds, and the bankruptcy of its top customer, Virgin Orbit. To boost its revenue and expand its ecosystem, it acquired the AI vision firm Pangiam last April.
Innodata went public back in 1993, but it didn't attract much attention because it was a small analytics software provider that increased its revenue at a compound annual growth rate (CAGR) of 6% from 1994 to 2018. But in 2018, it launched a suite of task-specific microservices that could efficiently prepare large amounts of data for AI applications.
Five of the " Magnificent Seven" companies subsequently hired Innodata to prepare their AI-oriented data, and its annual revenue surged at a CAGR of 20% from 2018 to 2024. Its business boomed because those large tech companies often spend 80% of their time preparing the data for a new AI project and just 20% of that time training the actual algorithm. To speed up that inefficient process, those tech giants outsourced the preparation of that data to Innodata.
Which company could grow faster over the next three years?
Over the next three years, BigBear.ai's growth should be driven by its swelling backlog of government contracts -- which include new digital ID and biometrics services for the Department of Homeland Security (DHS) at airports and other ports of entry, a modernization project for the U.S. military's Orion Decision Support Platform (DSP), and new supply chain initiatives. It could also attract more commercial clients as the macro environment warms up again.
During the same period, Innodata's growth should be fueled by the rapid expansion of the generative AI market, which should drive its big tech customers to ramp up their spending on its data preparation services. It will likely attract even more large customers.
Projected Revenue Growth
2025
2026
2027
BigBear.ai
6.1%
12.1%
No consensus yet
Innodata
41.5%
23.5%
5.1%
Data source: Marketscreener.
BigBear.ai's revenue growth is expected to accelerate in 2025 and 2026, but analysts have not yet set any firm forecasts for 2027. Innodata's revenue growth is expected to decelerate in 2026 and 2027 as it saturates its core customer base of Magnificent Seven customers, and its potential expansion into other markets hasn't been factored into those estimates yet.
BigBear.ai is not yet profitable, but analysts expect it to narrow its net losses through 2026. Innodata turned profitable in 2024, and analysts expect its net income to grow at a CAGR of 16% through 2027 as its pricing power in its niche market improves and economies of scale kick in.
Which stock is a better value right now?
With a market cap of $2.1 billion, BigBear.ai trades at 12 times this year's sales. Innodata, which is valued at $1.6 billion, trades at less than 7 times this year's sales.
BigBear.ai looks a bit pricey if its revenue growth doesn't accelerate in 2027 and beyond. Its growth in the government sector is encouraging, but those contracts can be less predictable than its commercial contracts. It's also still growing at a slower rate than higher-growth AI leaders such as Palantir.
Meanwhile, Innodata appears to be a better value because analysts' longer-term estimates for 2027 may be too conservative. With all that cash coming in from its Magnificent Seven customers, it could still have plenty of ways to expand both organically and inorganically over the next two years. So, while BigBear.ai and Innodata might both benefit from the secular expansion of the AI market, Innodata's stronger growth, higher profits, and lower valuation make it the better buy.
Should you invest $1,000 in BigBear.ai right now?
Before you buy stock in BigBear.ai, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and BigBear.ai wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $652,133!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,056,790!*
Now, it's worth noting Stock Advisor's total average return is 1,048% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of July 21, 2025
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
13 minutes ago
- CTV News
U.S. says tariff deadline of Aug 1 is firm, no extensions
U.S. President Donald Trump listens to members of the media after he arrived at Prestwick Airport in Ayrshire, Scotland, Friday, July 25, 2025.(AP Photo/Jacquelyn Martin) WASHINGTON — The U.S. deadline of August 1 for imposing tariffs on its trading partners is firm and there will be no extensions, U.S. Commerce Secretary Howard Lutnick said Sunday. 'So no extensions, no more grace periods. August 1, the tariffs are set. They'll go into place. Customs will start collecting the money, and off we go,' Lutnick told 'Fox News Sunday.' After the levies kick in, U.S. President Donald Trump -- who was negotiating Sunday in Scotland with European Union officials -- is still willing to keep talking, Lutnick said. Of the Europeans, Lutnick said, 'You know they're hoping they make a deal, and it's up to President Trump, who's the leader of this negotiating table. We set the table.' So far five countries have struck deals with the Trump administration ahead of the Friday deadline as it tries to overhaul the global system of largely free trade by slapping tariffs on countries that the United States deems as engaging in unfair practices. These five are Britain, Vietnam, Indonesia the Philippines, and Japan. The levies they accepted are often higher than the new base rate of 10 percent that the United States has applied to most countries since April. But they are far below the levels the Trump administration threatened to impose if no deal were reached. AFP
Globe and Mail
26 minutes ago
- Globe and Mail
Codex Labs to Exhibit at The Society for Pediatric Dermatology's 50th Annual Meeting
Seattle, Wash. - July 22nd, 2025 - Codex Labs, a biotech skincare company focused on microbiome-friendly solutions, is honored to participate in The Society for Pediatric Dermatology's (SPD) 50th Annual Meeting. Taking place from July 23rd to 26th at The Westin Seattle, the event will celebrate five decades of advancing pediatric dermatology through education, research, and collaboration. "Codex Labs is delighted to be attending The Society for Pediatric Dermatology's 50th Annual Meeting and presenting a novel plant-based biotech eczema lotion and cleanser for children as young as 3 weeks old,' says founder and CEO Dr. Barbara Paldus. 'We believe that these new topicals, when combined and targeted with pre- and probiotics, will usher in a future of highly effective, steroid-free alternatives for the management of pediatric atopic dermatitis." The SPD comprises over 1,800 members worldwide, including pediatricians, dermatologists, pediatric dermatologists, and other healthcare professionals. At this year's milestone 50th SPD Annual Meeting, Codex Labs will be one of many organizations gathering to support the advancement of pediatric dermatology. The SPD's 50th Annual Meeting will take place over four days and feature networking opportunities, support group discussions, lecture sessions, companies and exhibitors showcasing their products, and organizations dedicated to pediatric dermatology research and advancement. Some key topics highlighted at this year's meeting include infections, medications and therapies, psoriasis and inflammatory skin conditions, tumors and neoplasms, vascular lesions, and more. Codex Labs will be attending this year's 50th Annual Meeting and sponsoring the Early Career Networking Reception on Wednesday, July 23rd at 6:00 pm. This event is for medical doctors completing a fellowship or those out of training for five years or less, where they can share experiences and connect with other young dermatologists. Dr. Jessica Maloh, Naturopathic Doctor and Head of Naturopathic Medicine at Codex Labs, will be attending the event and presenting a research poster that highlights the use of oral probiotics as adjunctive interventions for acne. 'Acne is one of the most common skin conditions affecting adolescents, often impacting not only the skin, but also self-esteem and quality of life,' says Dr. Maloh. 'At the SPD, I'm excited to share a summary of the research on the adjunctive use of oral probiotics in acne management- an intervention that may complement conventional dermatologic treatments like antibiotics and oral isotretinoin. Integrative strategies like this have been found to enhance acne treatment efficacy while also supporting the gut microbiome.' Codex Labs is honored to participate in the 50th Annual Meeting and looks forward to showcasing its products and findings. Dr. Maloh invites guests to the Networking Reception and to visit her team's presentation to learn more about their skincare breakthroughs and the latest in integrative dermatology research. Event Details: Location: The Westin Seattle, located at 1900 5th Ave, Seattle, WA 98101. For more information about Codex Labs and its products, please visit If you are interested in learning more about Codex Labs' participation in The SPD's 50th Annual Meeting, please contact About Codex Labs: Based in Silicon Valley and led by scientist Dr. Barb Paldus, Codex Labs is committed to creating highly effective, clinically proven, microbiome-supporting skin-gut-brain-biome solutions that contain potent, biotech-derived plant-based actives. Codex Labs' products focus on restoring/protecting the skin barrier, managing inflammation, and addressing skin conditions associated with aging, acne, eczema, and psoriasis. The brand has been heralded by integrative dermatologists and naturopathic doctors for creating the next generation of effective, vegan, cruelty-free, and sustainable plant-based solutions.
CTV News
3 hours ago
- CTV News
As Trump's trade deal deadline approaches, his tariffs face legal pushback in court
U.S. President Donald Trump speaks during an event to announce new tariffs in the Rose Garden at the White House, on April 2, 2025, in Washington. (AP Photo/Mark Schiefelbein, File) WASHINGTON — Donald Trump's plan to realign global trade faces its latest legal barrier this week in a federal appeals court — and Canada is bracing for the U.S. president to follow through on his threat to impose higher tariffs. While Trump set an Aug. 1 deadline for countries to make trade deals with the United States, the president's ultimatum has so far resulted in only a handful of frameworks for trade agreements. Deals have been announced for Japan, Vietnam, Indonesia, the Philippines and the United Kingdom — but Trump indicated last week that an agreement with Canada is far from complete. 'We don't have a deal with Canada, we haven't been focused on it,' Trump told reporters Friday. Trump sent a letter to Prime Minister Mark Carney threatening to impose 35 per cent tariffs if Canada doesn't make a trade deal by the deadline. The White House has said those duties would not apply to goods compliant with the Canada-U.S.-Mexico Agreement on trade. Canadian officials have also downplayed expectations of a new economic and security agreement materializing by Friday. 'We'll use all the time that's necessary,' Carney said last week. Countries around the world will also be watching as Trump's use of a national security statute to hit nations with tariffs faces scrutiny in the United States Court of Appeals for the Federal Circuit. The U.S. Court of International Trade ruled in May that Trump does not have the authority to wield tariffs on nearly every country through the use of the International Economic Emergency Powers Act of 1977. The act, usually referred to by the acronym IEEPA, gives the U.S. president authority to control economic transactions after declaring an emergency. No previous president had ever used it for tariffs and the U.S. Constitution gives power over taxes and tariffs to Congress. The Trump administration quickly appealed the lower court's ruling on the so-called 'Liberation Day' and fentanyl-related tariffs and arguments are set to be heard in the appeal court on Thursday. The hearing combines two different cases that were pushing against Trump's tariffs. One involves five American small businesses arguing specifically against Trump's worldwide tariffs, and the other came from 12 states pushing back on both the 'Liberation Day' duties and the fentanyl-related tariffs. George Mason University law professor Ilya Somin called Trump's tariff actions a 'massive power grab.' Somin, along with the Liberty Justice Center, is representing the American small businesses. 'We are hopeful — we can't know for sure obviously — we are hopeful that we will continue to prevail in court,' Somin said. Somin said they are arguing that IEEPA does not 'give the president the power to impose any tariff he wants, on any nation, for any reason, for as long as he wants, whenever he feels like it.' He added that 'the law also says there must be an emergency and an unusual and extraordinary threat to American security or the economy' — and neither the flow of fentanyl from Canada nor a trade deficit meet that definition. U.S. government data shows a minuscule volume of fentanyl is seized at the northern border. The White House has said the Trump administration is legally using powers granted to the executive branch by the Constitution and Congress to address America's 'national emergencies of persistent goods trade deficits and drug trafficking.' There have been 18 amicus briefs — a legal submission from a group that's not party to the action — filed in support of the small businesses and states pushing against Trump's tariffs. Two were filed in support of the Trump administration's actions. Brent Skorup, a legal fellow at the Washington-based Cato Institute, said the Trump administration is taking a vague statute and claiming powers never deployed by a president before. The Cato Institute submitted a brief that argued 'the Constitution specifies that Congress has the power to set tariffs and duties.' Skorup said there are serious issues with the Trump administration's interpretation of IEEPA. 'We don't want power consolidated into a single king or president,' he said. It's expected the appeals court will expedite its ruling. Even if it rules against the duties, however, they may not be immediately lifted. White House Press Secretary Karoline Leavitt has said the Supreme Court should 'put an end to this.' There are at least eight lawsuits challenging the tariffs. Canada is also being hit with tariffs on steel, aluminum and automobiles. Trump used different powers under the Trade Expansion Act of 1962 to enact those duties. This report by The Canadian Press was first published July 27, 2025. Kelly Geraldine Malone, The Canadian Press
